Questions with Correct Answers
100% Verified Graded A+
1. A patient who is G2P2 at 32-week' gestation arrives at the triage unit complaining of
regular uterine contractions. Her pregnancy history includes a preterm delivery at 34
weeks. Prior to examining her, the nurse performs elec- tronic fetal monitoring and
obtains a complete history.The patient reports no bleeding and no rupture of membranes.
She has had no vaginal examinations or sexual activity for more than 24 hours. The
biochemical marker useful in this situation for predicting preterm birth is
a. cervical ferritin
b. fetal fibronectin
c. corticotropin-releasing hormone
d. placental alpha-microglobulin-1
Answer: b-fetal fibronectin (fFN) is uncommonly pre- sent in cervicovaginal secretions in
the late second and early third trimesters. fFN is and extracellular glycoprotein that is
thought to act as an adhesive between the fetal membrane and uterine wall and can be
1/
9
, disrupted by inflammation. A preterm birth within two weeks is probable after a positive
test result. Cervical ferritin is not a biomarker but an inflammatory marker whose
presence provide
support for the theory that infection is a mediator of preterm birth. Maternal plasma
concentrations of corticotropin-releasing hormone are elevated in both term and preterm
pregnancies. It appears to be a component of the common pathway of labor regardless of
gestation. Placenta alpha-microglobulin-1 is a protein found that is a biomarker for rupture
of membranes.
2. A patient comes to triage unit at 32 weeks' gestation concerned because she has been
"leaking fluid" from her vagina for the past hour. She says she has felt no contractions and
reports normal fetal activity. A bedside immunoassay called AmniSure is performed. The
test identifies a glycoprotein abundant in amniotic fluid. This glycoprotein is called
a. prolactin
b. alpha-fetoprotein
c. fetal fibronectin
d. placental alpha-microglobulin-1
Answer: d-Premature rupture of membranes is one the most common complications of
pregnancy resulting in a newborn's admission to the NICU. A bedside immunoassay test,
2/
9